Less than 10% of people who could benefit from obesity jabs including Wegovy are able to get them, states the WHO as it releases its inaugural guidance on the medications.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for more widespread and fairer access to GLP-1 medication.
According to forecasts, over two billion are projected to be obese by 2030 unless action is taken.
"The new guidance acknowledges that obesity is a chronic disease that can be managed with comprehensive and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major hurdles to universal access to the jabs that can aid individuals in losing considerable body mass, says the body.
Weight-Loss Drug Supply Crisis
Even under the present most favorable case, the manufacturing of these medications would only suffice for approximately 100 million people – under 10% of those who need them, per the health organization.
The advice urges nations and manufacturers to widen access, through measures including licensing agreements.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
How Weight-Loss Injections Operate
These medications imitate a natural hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so users reduce food intake.
Patients commonly see weight reduction within a few weeks of commencing the regular doses.
Studies suggests users may regain a significant portion a year later of halting the medication, because their normal hunger resume.
Being above a healthy weight elevates your likelihood for experiencing health problems, like diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight concerns people in all nations and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.
